Pacer Advisors
TEVA icon

Pacer Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Pacer Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$299K Sell
8,811
-440
-5% -$14.7K ﹤0.01% 1681
2026
Q1 		$279K Buy
9,251
+264
+3% +$8.49K ﹤0.01% 1650
2025
Q4 		$280K Sell
8,987
-314
-3% -$7.74K ﹤0.01% 1955
2025
Q3 		$188K Sell
9,301
-563
-6% -$9.89K ﹤0.01% 1975
2025
Q2 		$165K Sell
9,864
-475
-5% -$7.67K ﹤0.01% 1929
2025
Q1 		$159K Buy
10,339
+297
+3% +$5.3K ﹤0.01% 1841
2024
Q4 		$221K Buy
10,042
+396
+4% +$7.2K ﹤0.01% 1900
2024
Q3 		$174K Sell
9,646
-75
-0.8% -$1.31K ﹤0.01% 1884
2024
Q2 		$158K Sell
9,721
-475
-5% -$7.32K ﹤0.01% 1984
2024
Q1 		$144K Sell
10,196
-380
-4% -$4.79K ﹤0.01% 2262
2023
Q4 		$110K Buy
10,576
+294
+3% +$2.75K ﹤0.01% 2644
2023
Q3 		$105K Buy
10,282
+1,136
+12% +$10.6K ﹤0.01% 2205
2023
Q2 		$68.9K Buy
9,146
+552
+6% +$4.48K ﹤0.01% 2993
2023
Q1 		$76.1K Buy
8,594
+276
+3% +$2.73K ﹤0.01% 1678
2022
Q4 		$75.9K Buy
+8,318
New +$72.6K ﹤0.01% 2727
2022
Q1 		– Sell
-8,460
Closed -$68K – 2544
2021
Q4 		$68K Sell
8,460
-387
-4% -$3.49K ﹤0.01% 2111
2021
Q3 		$86K Buy
8,847
+276
+3% +$2.58K ﹤0.01% 1371
2021
Q2 		$85K Hold
8,571
– – ﹤0.01% 1358
2021
Q1 		$99K Sell
8,571
-460
-5% -$5.28K ﹤0.01% 1301
2020
Q4 		$87K Sell
9,031
-2,024
-18% -$19.4K ﹤0.01% 1379
2020
Q3 		$100K Buy
+11,055
New +$117K ﹤0.01% 1249
2020
Q1 		– Sell
-8,333
Closed -$82K – 1076
2019
Q4 		$82K Buy
8,333
+3,114
+60% +$27.8K ﹤0.01% 1158
2019
Q3 		$36K Buy
5,219
+1,760
+51% +$13.5K ﹤0.01% 1154
2019
Q2 		$32K Buy
+3,459
New +$41.7K ﹤0.01% 1126
2018
Q2 		– Sell
-96,859
Closed -$1.66M – 1199
2018
Q1 		$1.66M Buy
96,859
+27,526
+40% +$537K 0.09% 261
2017
Q4 		$1.31M Buy
69,333
+29,425
+74% +$443K 0.09% 292
2017
Q3 		$702K Buy
39,908
+2,090
+6% +$47K 0.06% 474
2017
Q2 		$1.26M Buy
+37,818
New +$1.17M 0.12% 154
2013
Q4 		$459K Buy
+7,979
New +$314K 0.11% 237

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Pacer Advisors's TEVA Position: Q2 2026 in Review

Pacer Advisors reduced its Teva Pharmaceuticals (TEVA) stake by 4.8% in Q2 2026, selling an estimated $14.7K and leaving 8,811 shares worth $299K. The position accounts for ﹤0.01% of the portfolio, ranked #1681.

Pacer Advisors first reported a position in TEVA in Q4 2013 and has held it in 29 quarters since. The position peaked at $1.66M in Q1 2018. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Pacer Advisors held 8,811 shares of Teva Pharmaceuticals worth $299K as of Q2 2026.
  • Pacer Advisors sold 440 Teva Pharmaceuticals shares in Q2 2026, an estimated $14.7K.
  • Teva Pharmaceuticals made up ﹤0.01% of Pacer Advisors's portfolio in Q2 2026, its #1681 holding.
  • Pacer Advisors first reported a position in Teva Pharmaceuticals in Q4 2013 and has held it in 29 quarters since.
  • Pacer Advisors's Teva Pharmaceuticals position peaked at $1.66M in Q1 2018.
  • 673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Pacer Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.